CONSTANT LEVERAGE SHORT - NOVO-NORDISK B | Market Closed - Euronext Paris 10:00:01 03/06/2024 pm IST | ||
| 0.105 EUR | -0.94% |
|
| Current month | -0.94% | ||
| 1 month | -38.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 0.105 | -0.94% |
| 31/24/31 | 0.106 | -3.64% |
| 30/24/30 | 0.11 | -2.65% |
| 29/24/29 | 0.113 | +2.73% |
| 28/24/28 | 0.11 | +1.85% |
Real-time Euronext Paris
Last update June 03, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| 2FLMB | |
| ISIN | NLBNPNL2IDU5 |
| Date issued | 20/09/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.63 € |
|---|---|
| Lowest since issue | 0.096 € |
| Spread | 0.005 € |
| Spread % | 4.63% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
923.9
DKK
Average target price
917.2
DKK
Spread / Average Target
-0.72%
- Stock Market
- Certificates
- 2FLMB Certificat
